 Study participants recruited from the Pharmacogenomic Evaluation of Antihypertensive Responses studies; PEAR 201-2005 and PEAR-2 271-2010 funded by the National Institutes of Health. Participants in the study have completed either PEAR or PEAR-2 studies 